DNA test could Fine-Tune blood thinners for heart patients

NCT ID NCT06143709

Ongoing Knowledge-focused Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This registry studies how genetic information can help doctors choose the best antiplatelet medication for people who have had a heart stent procedure. Over 1,600 participants will provide DNA samples and be followed for 12 months to track heart events and bleeding. The goal is to learn how to personalize therapy based on genetics and other patient factors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DNA sample collection
What this could lead to: If successful, this could help doctors personalize antiplatelet medications based on a patient's genetics, potentially reducing heart attacks and strokes while minimizing bleeding risks.
What could go wrong: This is an observational registry, not a treatment trial, so it won't directly test a new drug or therapy. Results may not lead to immediate changes in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE PERCUTANEOUS CORONARY INTERVENTION

Contacts and locations

Locations

University of Florida

Gainesville, Florida, 32609, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.